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Abstract
Background: The processes that compose expression of a given gene are far more complex than previously thought
presenting unprecedented conceptual and mechanistic challenges that require development of new tools. Chromatin
structure, which is regulated by DNA methylation and histone modification, is at the center of gene regulation.
Immunoprecipitations of chromatin (ChIP) and methylated DNA (MeDIP) represent a major achievement in this area
that allow researchers to probe chromatin modifications as well as specific protein-DNA interactions in vivo and to
estimate the density of proteins at specific sites genome-wide. Although a critical component of chromatin structure,
DNA methylation has often been studied independently of other chromatin events and transcription.
Results: To allow simultaneous measurements of DNA methylation with other genomic processes, we developed
and validated a simple and easy-to-use high throughput microplate-based platform for analysis of DNA
methylation. Compared to the traditional beads-based MeDIP the microplate MeDIP was more sensitive and had
lower non-specific binding. We integrated the MeDIP method with a microplate ChIP assay which allows
measurements of both DNA methylation and histone marks at the same time, Matrix ChIP-MeDIP platform. We
illustrated several applications of this platform to relate DNA methylation, with chromatin and transcription events
at selected genes in cultured cells, human cancer and in a model of diabetic kidney disease.
Conclusion: The high throughput capacity of Matrix ChIP-MeDIP to profile tens and potentially hundreds of
different genomic events at the same time as DNA methylation represents a powerful platform to explore complex
genomic mechanism at selected genes in cultured cells and in whole tissues. In this regard, Matrix ChIP-MeDIP
should be useful to complement genome-wide studies where the rich chromatin and transcription database
resources provide fruitful foundation to pursue mechanistic, functional and diagnostic information at genes of
interest in health and disease.
Background
The study of chromatin biology has emerged as a new
paradigm to understand the pathophysiology of critical
events responsible for diseases such as cancer [1-3], dia-
betes [4,5], cardiomyopathies [6], ageing [7] and many
others. Chromatin is a compact, but remarkably dynamic,
structure that plays a critical role in transcription, DNA
replication and repair [8,9]. Its structure and function is
regulated through covalent modifications of DNA and
nucleosome histones as well as substitution by a variety
of histone variants.
Mammalian DNA can be modified by cytosine methy-
lation which involves the addition of a methyl group to
t h e5p o s i t i o no fac y t o s i n e( 5 m C )g e n e r a l l y ,b u tn o t
always [10], preceding guanosine in the DNA sequence
(cytosine-phosphate-guanine, CpG). Mammalian DNA
methylation is mediated by DNA methyltransferases
(DNMTs) including DNMT1 (responsible for maintain-
ing proper methylation levels during replication and pos-
sibly DNA repair), DNMT3a and DNMT3b (responsible
for de novo methylation during embryogenesis) [11].
CpG islands are genomic regions that contain a high fre-
quency of CpG sites typically > 300 base pairs in length.
Most studies have focused on methylation of CpG islands
in the gene’s promoter region where it is associated with
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blockade of transcription factor binding to genomic tar-
gets [13]. Although methylation of CpG islands nested
within transcribed regions has not been extensively stu-
died, new evidence suggests that the role of DNA methy-
lation in transcription elongation and termination is just
as important as CpG methylation in the regulation of tran-
scription initiation [14-16]. Because of its importance in
biology of disease several different methods were devel-
oped to assay DNA methylation. Bisulfite sequencing,
bisulfite conversion-based MethyLight, methylation-sensi-
tive digestion, and methyl-DNA immunoprecipitation
(MeDIP) are some of the well established methods to
assay DNA methylation both at specific sites and genome-
wide [10,17-20]. Because of its simplicity and low cost
MeDIP is increasingly becoming a popular method [21].
Histone post-translational modifications (PTMs; e.g.,
include acetylation, methylation, and phosphorylation) are
the major avenues that regulate chromatin dynamics: they
expose, or close, docking sites for a host of other mole-
cules, including chromatin remodeling and transcription
factors [9,22,23]. To date, more than 100 different histone
amino acid residues have been shown to be modified
[9,24,25]. A host of enzymes that modify specific histone
amino acid residues have been identified [8,9,24]. These
include, but are not limited to, histone methyltransferases
[9], demethylases [26], acetyltransferases [27], deacetylases
[28], kinases [29,30] and phosphatases [31]. Many, if not
most of these enzymes, are directly recruited to specific
genomic regions, for example, very recently kinases
[32-36] and phosphatases [31,36-38] were discovered to be
directly recruited to their target genes. The significant pro-
gress in this area of research was facilitated by the intro-
duction of the chromatin immunoprecipitation (ChIP)
assay [39-41].
Although chromatin studies are providing compelling
evidence for dynamic interchange between histones and
DNA methylation [42], typically DNA methylation and his-
tone modification studies have been done independently of
each other and most often by different laboratories using
low throughput technologies. Here, we describe a simple
and easy-to-use microplate-based platform for combined
analysis of DNA methylation, histone modifications and
chromatin-bound enzymes, Matrix ChIP-MeDIP.
Methods
Reagents
Bovine serum albumin (BSA), phosphate buffered saline
(PBS), salmon sperm DNA, transfer RNA (tRNA), 5-aza-
2’-deoxycytidine (DAC), trichostatin A (TSA), and protein
A were from Sigma, and proteinase K was from Invitro-
gen. Matrix ChIP-MeDIP 96-well polypropylene plates
were from Bioexpress. Formaldehyde, ethanol, NaCl,
EDTA, Triton X-100, NP-40, Tris-HCl, leupeptin, PMSF,
p-nitrophenyl phosphate, NaF, Na3VO4,N a 2MoO4 and
b-glycerophosphate were from Sigma. Dulbecco’sM o d i -
fied Eagle Medium (DMEM), McCoy’s medium, penicil-
lin/streptomycin (P/S), Glutamax, fetal bovin serum (FBS),
trypsin/EDTA were obtained from Invitrogen. The antibo-
dies were commercially available as listed in Table 1.
Cell Lines and Treatment
HeLa cells were obtained from the American Type Cul-
ture Collection (ATCC, Manassas, VA), and grown in
DMEM supplemented with P/S (0.5 units/ml), Glutamax
(2 mmol/l), and 10% (v/v) FBS.
For inhibitor studies, HeLa cells were seeded in T150
tissue culture flasks at a low density and treated with 200
nmol/l of DAC for 3 days and 300 nmol/l of TSA for the
last 24 hours. Media containing fresh drugs was replaced
daily. Controls consisted of cells treated identically with
drug solvents (PBS and 100% ethanol), and all experiments
were done in triplicate. After treatment, cells were
removed from flasks using trypsin/EDTA solution and
rinsed with PBS. Cell pellets were ready for chromatin or
DNA isolation.
Human cervical tissues
Ten frozen cervical tissue samples (5 with normal histol-
ogy and 5 with invasive cervical cancer) were selected
from our established IRB-approved specimen repository at
University of Washington. These samples were collected
from our previous studies conducted in Senegal investigat-
ing the relationship between cervical neoplasia, HIV infec-
tion, and inflammation [43].
Mice
Two-month-old male FVB and OVE26 mice on FVB back-
ground [44] and two-month- old C57BL/6 and C57BL/6
ob/ob [36] mice were purchased from The Jackson
Laboratory (Bar Harbor ME and were maintained and
sacrificed as described previously [45]. Blood was collected
just prior to sacrifice. Subsequently, kidneys were removed
and flash frozen in liquid nitrogen. Blood glucose was
measured using One Touch Ultra system (LifeScan Inc.).
All procedures were done in accordance with current NIH
guidelines and approved by the Animal Care and Use
Committee of the University of Washington.
Chromatin and DNA preparation
For ChIP assays, cell pellets (10
6 cells) or tissues (10-20
mg) were cross-linked with formaldehyde final concentra-
tion 1.42% for 15 minutes at room temperature and then
formaldehyde was quenched with 125 mM glycine for 5
minutes at room temperature as previously described [46].
Cross-linked cells/tissues were lysed using IP buffer [150
mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.5% NP-40,
50 mM Tris-HCl (pH 7.5)] containing 10 μg/μl leupeptin,
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Antibody Catalog
No.
Source Manufacturer Peptide immunogen
Flag M2 F 1804 Murine
monoclonal
Sigma Recognize a FLAG peptide sequence at the N-terminus, Met-N-terminus, C-terminus, or internal sites of a fusion protein
H2A.Z 39113 Rabbit polyclonal Active Motif C-terminus of human histone H2A.Z
H3K9/14Ac 06-599 Rabbit polyclonal Millipore KLH-conjugated peptide corresponding to amino acids 1-20 of Tetrahymena histone H3 (ARTKQTAR[K*]STGG[K*]APRKQLC) where K*
is acetylated.
H3K27m3 Ab6002 Mouse
monoclonal
Abcam Synthetic peptide derived from residues 1-100 of human histone H3, trimethylated at K27
mCpG AMM99021 Mouse
monoclonal
Aviva 5-methylcytosine conjugated to ovalbumin
mCpG MAb-
5MECYT
Mouse
monoclonal
Diagenode Raised against 5-methyl Cytidine conjugated to
ovalbumine
Pol II CTD
(4H8)
Sc-47701 Mouse
monoclonal
Santa Cruz C-terminal domain peptide
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50.5 mM PMSF, 30 mM p-nitrophenyl phosphate, 10 mM
NaF, 0.1 mM Na3VO4, 0.1 mM Na2MoO4, and 10 mM b-
glycerophosphate [47,48]. Chromatin was sheared using
Diagenode Bioruptor (100 µl IP buffer, 30 rounds 30 sec-
onds ON/30 seconds OFF, high power, 4°C). The suspen-
sion was cleared by centrifugation at 12,000 g (10 minutes
at 4°C), and the supernatant, representing sheared chro-
matin, was aliquoted and stored at -80°C. DNA input was
prepared by incubation sheared chromatin with proteinase
K (0.2 μg/μl) for 15 minutes at 55°C, followed by 15 min-
utes at 95-100°C in a PCR cycler.
For MeDIP, single stranded DNA (ssDNA) was isolated
from HeLa cell pellets, and tissues using Omega Bio-Tek
Tissue DNA Kit (Norcross, GA), followed by ultrasound-
shearing and denaturation (boiling 10 minutes). We found
that using the proteinase K method (as above) for DNA
purification from uncross-linked and cross-linked sheared
chromatin gave the same MeDIP results. Thus, the same
cross-linked sheared sample can be used for input chro-
matin in ChIP and for purification of ssDNA as input for
MeDIP assays. For MeDIP, purified DNA was treated with
1n g / μl RNase.
Microplate-based immunoprecipitation (Figure 1)
Step1. Protein A-coated microplate preparation
UV-irradiated 96-well plates were coated with protein A
by incubating overnight at room temperature with 20-
100 μlo f2μg/μl protein A in PBS per well. Parafilm-
sealed plates were stored up to 2 weeks (4°C) without loss
of activity. The same microplate(s) was used for ChIP and
MeDIP assays- typically 1-3 rows of wells were used for
MeDIP and the rest for ChIP.
Step2. Blocking well walls
Prior to use, plates were washed twice with 200 μl of PBS
and well walls were blocked with 200 μl of blocking buffer
for 60 minutes at room temperature. The wells used for
MeDIP were blocked with IP buffer/5% BSA (MeDIP
blocking buffer) and those for ChIP with IP buffer/5%
BSA containing 100 μg/ml sheared salmon sperm DNA
(ChIP blocking buffer). In all steps, vacuum aspirator
wand was used to clear wells of buffers.
Step3. Attachment of ChIP antibodies to well walls
ChIP wells were cleared of blocking buffer and then ChIP
antibodies diluted in ChIP blocking buffer were incubated
in these “ChIP” wells for 60 minutes at room temperature.
Wells were cleared and then appropriate amount of
sheared chromatin diluted in ChIP blocking buffer was
added to “ChIP” wells.
Step4. Pre-incubation of 5mC antibody with denatured
ssDNA
Sheared ssDNA (0.1-1 ng DNA/μl) was pre-incubated
(either plain tubes or 96-well plates) in MeDIP blocking
buffer with anti-5mC antibody in an ultrasonic water
bath (Branson 3510) for 60 minutes at 4°C. And then the
mixture was transferred to blocked “MeDIP” wells. The
reaction volume varied depending on the number of
genes to be studied. Steps 3-4 were done at the same
time.
Step5. Capture of methylated ssDNA and chromatin to well
walls
Microplate(s) were covered with a sealing film and cap-
ture of chromatin and DNA complexes to well walls was
done by floating the microplates in ultrasonic water bath
(Branson 3510) for 60 minutes at 4°C.
Step6. Well washes
Wells were washed three times with ice-cold IP buffer fol-
lowed by three washes with ice-cold TE buffer (pH 7.0).
Step7. Elution of PCR-ready DNA
After washes, appropriate amount of elution buffer (25
mM Tris, pH 10, 1 mM EDTA, and 0.2 μg/μlp r o t e i n a s eK
containing 1% IP buffer) was added to each well. Input
DNA was prepared by adding the same amount of chro-
matin/DNA to wells containing elution buffer on the same
plate as the ChIP-MeDIP samples. The plates were then
sealed with PCR sealing film. PCR-ready DNA was eluted/
purified in a 96-well PCR cycler applying one cycle of
heating (55°C for 15 minutes) followed by one cycle to
reverse cross-linking and to inactivate proteinase K (95°C
for 15 minutes).
Beads MeDIP
Immunoprecipitation of methylated DNA using beads was
done using an adaptation of the Fast ChIP method [46].
Briefly, sheared ssDNA was pre-incubated in MeDIP
blocking buffer (30 μl) with anti-5mC antibody in either
96-well plates or plain tubes in an ultrasonic water bath
(Branson 3510) for 60 minutes at 4°C. The mixture was
then transferred to fresh tubes containing 10 μl of washed
protein A agarose beads (Pharmacia). The slurry was
rotated for 30 minutes (4°C) and then the beads were
washed three times with 1 ml of cold IP buffer and three
times with 1 ml of cold TE buffer containing no inhibitors.
Then 60 μl of 10% Chelex/Proteinase K (100 μg/ml) was
added to the beads and the slurry was incubated for 30
minutes at 55°C while shaking, followed by another round
of boiling for 10 minutes. Suspension was centrifuged and
supernatant was collected. Eluate was used directly as a
template in PCR analysis.
PCR analysis
1-2 μlo fe l u t e dD N Aw a su s e di n2 - 4μl real-time PCR
reactions (ABI7900HT). All PCR reactions were run in
triplicate. PCR primers were designed using the Primer3
software (http://frodo.wi.mit.edu/) and shown in Table 2.
PCR calibration curves were generated for each primer
pair from a dilution series of sheared total human or
mouse genomic DNA. The PCR primer efficiency curve
was fit to cycle threshold (Ct) versus log (genomic DNA
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Page 4 of 15Figure 1 Diagram of the microplate-based Matrix ChIP-MeDIP method. Batches of polypropylene plates are coated overnight with protein
A (room temperature) and are then stored sealed up to 2 weeks (4°C) and used when needed. Starting with protein A-coated plates the ChIP-
MeDIP assay takes 4-5 hours to generate PCR-ready DNA. Detailed protocol is described in “Method” section. The red and yellow lines exemplify
rows of wells with ChIP and MeDIP antibodies, respectively.
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Page 5 of 15Table 2 PCR primers.
Species Gene Purpose Forward Reverse Probe
Human ALU Real-time PCR CGGTGGCTCACGCCTGTA GAGTGCAGTGGCGCGATC
Human ALU MethyLight GGTTAGGTATAGTGGTTTATATTTGTAATTTTAGTA ATTAACTAAACTAATCTTAAACTCCTAACCTCA CCTACCTTAACCTCCC
Human LINE Real-time PCR ACGGAATCTCGCTGATTGCT CGTTGCCGCCTTGCA
Mouse MCP-1 Real-time PCR GAATGAAGGTGGCTGCTATG AACCCAGAAACATCCAATTCTC
Human SFRP1 Real-time PCR CTTACCTTGGGGCTTGGAG CTACTGGCCCGAGATGCTTA TTTCGCGTTTTTTTGT
Human SPARC Real-time PCR GGTTTCCTGTTGCCTGTCTC GGGGGTCACACATACCTCAG
Human SPARC MethyLight TTTCGCGGTTTTTTAGATTGTTC CATACCTCAATAACAAACAAACAAACG CAAAACGCGCTCTC
Mouse TGF-b1 Real-time PCR TTTGAGACTTTTCCGCTGCT AATAGGGGCGTCTGAGGAAC
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5dilutions) using an r-squared best fit. DNA concentration
values for each ChIP-MeDIP and input DNA samples
were calculated from their respective average Ct values.
Levels of 5mC, Pol II, enzymes and histone marks in
immunoprecipitated samples were expressed as a copy
number ratio of sample immunoprecipitated with specific
antibody to that of input DNA (% Input) [47].
MethyLight assay
MethylLight assays were done using established protocols
[19]. Briefly, CpG island sequences were identified using
t h eU n i v e r s i t yo fC a l i f o r n i aS a n t aC r u zg e n o m eb r o w s e r
(http://genome.ucsc.edu/) or from genomic information
using CpGPlot (http://www.ebi.ac.uk/emboss/cpgplot/).
MethyLight primers and MGB probes were designed
using Primer Express (ABI). Sequences of primers and
probes are listed in Table 2. Cervical tissue DNA was
converted using EpiTect Bisulfite Kit (Qiagen). For
MethyLight, 1 µl of bisulfite-converted DNA solution
was combined with 600 nmol/l of each primer and 200
nmol/l of probe in ABI Universal PCR Master Mix and
amplified under the default cycling conditions for Prism
HT7900 instrument. Human sperm DNA and human
sperm DNA methylated in vitro using the SssI (CpG)
methylase (New England Biolabs, Beverly, MA), respec-
tively, were used as U (unmethylated) and M (fully
methylated) control DNA. Copy number of specific genes
in samples was obtained using the standard curve gener-
ated from known amount of bisulfite-converted M
sequence. The “percent of methylated reference” (PMR)
values were calculated using a formula: ([geneX mean
value for the sample]/[ALU mean value for the sample])/
([geneX mean value for the M.SssI reference]/[ALU
mean value for the M.SssI reference])*100% [49].
Results and Discussion
MeDIP is typically done in test tubes with anti-5mC anti-
body immobilized to beads employing either centrifuga-
tion or a magnet [18]. Our goal was to develop a simple
and low cost high-throughput microplate-based MeDIP
method that could be used in combination with chroma-
tin immunoprecipitation [47].
Microplate-based MeDIP method development
The standard MeDIP protocol consists of several steps.
i) isolation of genomic DNA. ii) DNA fragmentation. iii)
DNA denaturation to generate single-stranded DNA. iv)
immunoprecipitation of methylated DNA fragments
using an antibody to 5mC. v) detection of specific
sequence(s) by PCR or other methods. The abundant
ALU and LINE repetitive elements are heavily methy-
lated and have been used as surrogates to assess global
DNA methylation [50]. SFRP1 gene is also methylated
[51] and was used as another test gene. Treatment of
cells with DNA methylation inhibitor DAC has pre-
viously been shown to decrease methylation of both
ALU and LINE elements [43]. We used cervical carci-
noma HeLa cells treated with or without methylation
inhibitors and tested these genes as readouts to develop
a microplate-based MeDIP protocol.
The most critical step was to develop a high efficiency
specific immunocapture of methylated DNA fragments
to well walls while maintaining low background binding.
To do that we used 96-well protein A-coated polypropy-
lene plates that have lower background binding than
polystyrene plates. To minimize non-specific binding in
microplate ChIP assay we blocked the well walls with 5%
BSA and sheared salmon sperm DNA in IP buffer [47].
G i v e nt h a ts a l m o ns p e r mD N Ai sa l s om e t h y l a t e d ,i t
could not be used for blocking the well walls. Thus, we
tested several blocking media: BSA, BSA combined with
tRNA or microccocal DNA. We found that BSA alone
was as good blocker of non-specific binding of sheared
denatured DNA as having it combined with either tRNA
or microccocal DNA. Thus, in MeDIP we used 5% BSA
in IP buffer as a blocking means to minimize non-specific
binding of DNA.
In microplate-based ChIP assay antibodies are first
attached to protein A-coated well walls, then sheared
chromatin in blocking buffer is added to wells and chro-
matin immunocapture is carried out using low energy
ultrasound [47]. We found that with this approach
immunocapture efficiency of methylated DNA using
anti-5mC antibody was low. In bead-based ChIP assay
the immunocapture is more efficient when the chromatin
is first pre-incubated with antibody and then the mixture
is added to the beads [46]. Thus, we compared immuno-
capture efficiency when either the DNA was added to
wells coated with protein A and anti-5mC antibody with-
out pre-incubation or when the DNA was first pre-incu-
bated in ultrasonic bath with the anti-5mC antibody and
then the mixture was added to protein A-coated wells.
Binding was done with 96-well plates floating in ultraso-
nic bath to facilitate antibody-antigen binding [46]. After
washes, DNA was eluted from the well walls and ana-
lyzed in real-time PCR using primers to ALU and LINE
elements as well as SFRP1.A ss h o w ni nF i g u r e2 A ,p r e -
incubation with the anti-5mC antibody increased the effi-
ciency of immunocapture by 10-20 folds. These results
also show that the level of DNA pull-down from HeLa
cells treated with DNA methylation inhibitor was lower
compared to untreated cells, providing evidence for anti-
5mC antibody specificity. The modest DAC-induced
decrease in DNA-methylation is similar in magnitude to
that reported in other cell lines using bisulfate PCR [50].
To further confirm specificity of the pull-down we
compared DNA immunocapture using different mono-
clonal anti-5mC antibodies from two vendors, Diagenode
Yu et al. BMC Molecular Biology 2011, 12:49
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Page 7 of 15and Aviva. Monoclonal Flag antibody was used as the
mock control. Figure 2B shows that the level of immuno-
capture with Diagenode and Aviva anti-5mC antibodies
were similar, and the specific signal was 10-20 times
greater than that with the mock Flag antibody. Taken
together these results indicate that the microplate-based
procedure allows specific immunocapture of methylated
DNA.
Figure 2 Optimization and testing the microplate-based MeDIP. HeLa cells were treated with 200 nM of DAC for 3 days and 300 nM of TSA for
the last 24 hours. Media containing fresh drugs was replaced daily. Control cells (vehicle) treated identically with drug solvents (PBS and 100%
ethanol). Cells were trypsinized and washed with PBS. For MeDIP input DNA was deproteinized using proteinase K, sheared by ultrasound
(Bioruptor), RNase treated and denatured. Assays were done using in-lab made protein A-coated polypropylene 96-well plates. A, MeDIP was tested
either when anti-5mC antibody (Diagenode) was first attached to wells and then DNA was added (No) or the DNA was preincubated (Yes) with the
antibody first and then the mixture was added to protein A-coated 96-well plates and binding was done in ultrasonic bath. After the binding step,
wells were washed, DNA was eluted and used in real-time PCR using primers to ALU and LINE elements as wells as the SFRP1 gene. B, MeDIP was
done with the preincubation step using monoclonal anti-5mC antibodies from either Diagenode (5mC-D) or Aviva (5mC-A) companies.
Monoclonal anti-Flag tag antibody was used as control. Results are expressed as % Input, mean ± SEM of three independent biological replicates.
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Page 8 of 15Next we compared performance of the microplate and
beads MeDIP assays (Figure 3). A range of HeLa cell
total DNA input were pre-incubated with either anti-
5mC or Flag (mock) antibody as above in ultrasonic
bath. After binding, equal aliquots of the antibody-DNA
mixture were incubated either with suspension of pro-
tein A beads or added to the protein A-coated micro-
plate wells. Beads and wells were washed with same
buffers and DNA was purified from the beads with Che-
lex [46] and from the well walls with elution buffer as
above [47]. Proteinase K was used in both methods as
before [46,47]. Purified DNA was analyzed in real-time
PCR using primers to ALU, LINE elements as well as
the known methylated H19 imprinted control region
(H19 ICR) or the unmethylated promoter region of the
housekeeping gene UBE2B [18]. Comparison of the
microplate and beads MeDIP at the highly abundant
ALU and LINE elements loci showed similar efficiency
of immunoprecipitation with the two methods, approxi-
mately 20-40% of input. The level of immunoprecipita-
tion was approximately the same for the input DNA
range tested (3-150 ng of DNA in 30 μl reaction
volume). Although the non-specific binding was higher
with the beads method, the specific binding was simi-
larly high with the two methods due to abundance of
the heavily methylated ALU and LINE.W h e nt e s t e do n
the single copy imprinted H19 ICR locus, the perfor-
mance of the microplate MeDIP was superior to the
beads method. To more quantitatively compare the spe-
cific and non-specific binding the 5mC immunocapture
signal was divided by the Flag signal [46]. In the range
of DNA input tested the specific signal measured with
the beads was approximately 2-fold over the background
compared to 5-8-fold for the microplate. The difference
in performance between the two methods was more
pronounced at the low level of DNA input (3 ng DNA)
where the specific 5mC signal was not different from
Flag background using beads, but 4-5 folds higher using
the microplate. With either method, at the unmethy-
lated UBE2B site the 5mC signal was not different from
the Flag background. We used 1 μlo ft h eM e D I PD N A
template per real-time PCR reaction which was done in
triplicates. Thus, at the lowest DNA amount input (3
ng) the microplate MeDIP method was sufficiently sen-
sitive to test methylation at nine different genomic sites
(3 ng in 30 μl volume/well for 5mC and Flag each, total
9n gD N Aa m o u n ti n c l u d i n gi n p u tD N Ae q u i v a l e n tt o
~1500 cells, or ~150 cells/one genomic site).
The schematic diagram of the combined ChIP-MeDIP
microplate method is illustrated in Figure 1. Starting
with chromatin one individual can generate 96-384
PCR-ready DNA samples in 4-5 hours (1-4 of 96-well
plates).
Application of Matrix ChIP-MeDIP to clinical cancer
samples: Combined ChIP-MeDIP demarcates cancer from
normal tissue better than MeDIP alone
Altered Pol II transcription and chromatin structure is one
of the critical hallmarks of cancer [52], a feature that has
been heavily exploited to search for tumor biomarkers that
could have diagnostic, prognostic and therapeutic applica-
tions. Until now, these studies have largely relied on using
either DNA methylation or histone marks but not both.
Given the fact that the cancer phenotype reflects extensive
alterations in the chromatin structure the capability to inte-
grate Pol II profile, DNA methylation and histones infor-
mation at cancer-critical loci will not only advance our
understanding of transcription/chromatin biology of cancer
but should also yield better tumor biomarker.
Using MethyLight we have previously identified several
genes that are methylated in cervical cancer, including
SPARC [43]. We tested five normal human cervical tissues
and five cervical cancer specimen using matrix ChIP-
MeDIP assays (Figure 4). In agreement with our previous
results [43] most of the cancer samples had higher levels
of SPARC methylation assayed using either MethylLight
(row 1)o rM e D I P( row 2), suggesting that the gene is
silenced in cervical cancer. Consistent with this suggestion
SPARC Pol II levels (row 3) and histone marks levels (rows
4-6) were lower in cancer samples. For most of the sam-
ples there was a clear difference in SPARC methylation
and histone marks in cancer compared to normal tissues.
However the demarcation of cancer versus normal tissue
was greater when DNA methylation was calculated as
either Pol II or a histone mark ratio (Figure 5). Although
this is a small pilot cohort, this simple example of an inte-
grative analysis suggests that Matrix ChIP-MeDIP could
b eam o r es p e c i f i ca n ds e n s i t i v em e t h o dt od i f f e r e n t i a t e
tumor from normal tissues and that as few as one gene
could be sufficient to make the distinction. The capability
of the Matrix ChIP-MeDIP platform to assay DNA methy-
lation and histone marks along with Pol II and enzyme
recruitment to cancer-critical genes provides an avenue
for more extensive integrative analysis to develop combi-
natorial biomarker panels to better characterize tumors
diagnostically, prognostically and therapeutically. In this
regard, cancer genome-wide chromatin studies and data-
base resources could be used to exploit the Matrix ChIP-
MeDIP platform.
Application of Matrix ChIP-MeDIP to animal models of
diabetic complication: Combined ChIP-MeDIP reveals
diabetes-induced reciprocal changes in the levels of DNA
methylation and Pol II at an inflammatory gene in
diabetic kidney
Diabetic kidney disease, or diabetic nephropathy, is a
major cause of kidney failure world-wide [53]. Chromatin
Yu et al. BMC Molecular Biology 2011, 12:49
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Page 9 of 15Figure 3 Validation of microplate-based MeDIP assay. A, Denatured HeLa cell DNA was preincubated with either monoclonal anti-5mC or
Flag (mock control) monoclonal antibody (0.5 μg each) in binding buffer (60 μl, 60 minutes at 4°C) in ultrasonic bath. After antibody
preincubation, the mixture was divided into two 30 μl aliquots, one was used in microplate MeDIP (Microplate MeDIP) and the other in protein
A-agarose beads MeDIP (Beads MeDIP). For each step the same buffer volumes were used in microplate- and beads-based assays. The X-axis
shows total DNA input used per IP (nanograms DNA/30 μl IP reaction). After binding, wells and beads were washed with IP buffer and TE buffer.
DNA was purified from well walls using 60 μl elution buffer/proteinase K and from beads using 60 μl 10% Chelex/proteinase K [46]. Eluted DNA
was used in real-time PCR using primers to ALU and LINE elements. Results are expressed as % Input, mean ± SEM of three independent
biological replicates. B, As in (A) microplate and beads immunoprecipitated DNA was used in real-time PCR using primers to either the
methylated H19 imprinted control region (H19 ICR) or the unmethylated promoter region of the house keeping gene UBE2B [18]. Data are
expressed as ratio of the 5mC signal to the Flag mock (5mC/Flag). The red horizontal line represents background binding, 5mC/Flag ratio = 1.
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Page 10 of 15biology of diabetic complications is merely a nascent field
and only a very few studies examined chromatin changes
in diabetic kidneys [54-56]. The progress in this area has
been hampered by the lack of sufficiently sensitive meth-
ods to measure renal chromatin changes at specific gene
loci in a diabetic milieu. Low grade inflammation trig-
gered by the components of diabetic milieu is one of the
contributors to this disease. In diabetic kidney disease
there is early increase in the expression of the monocyte
chemoattractant protein 1 (MCP-1) which promotes
inflammation, kidney injury and fibrosis [57]. Later in the
course of the disease there is enhanced expression of the
transforming growth factor b (TGF-b1), which may
result, in part, from the increased production of MCP-1
[58]. Both the MCP-1 and the TGF-b1 genes have CpG
located in the vicinity of transcription start site.
The OVE26 mice on FVB background overexpress cal-
modulin gene in pancreatic b cells, resulting in hyper-
glycemia and early onset of type 1 diabetes and diabetic
Figure 4 Comparison of MethyLight and Matrix ChIP-MeDIP
assay of normal cervix tissue and cervical cancer. MethyLight,
DNA purified from clinical cancer and normal tissues was bisulfite-
converted and amplified using SPARC gene primer in Taqman PCR
[43]. Methylight results are expressed as PMR values for each
individual sample. ChIP-MeDIP, frozen (-80°C) archived cervical tissue
samples histologically classified as normal and cancer were thawed,
minced and fixed with formaldehyde. After glycine treatment and
washes samples were treated with high energy ultrasound to shear
the chromatin. The lysates were cleared by centrifugation, aliquoted
and stored (-80°C). For MeDIP the input was deproteinized, RNase-
treated and denatured DNA. MeDIP was done using anti-5mC
antibody (Aviva) and ChIP assays with anti-Pol II CTD, H3K9/14Ac,
H2A.Z and H3K27m3 antibodies. MeDIP and ChIP DNA were
analyzed at the indicated site of the SPARC gene in real-time PCR.
Data represent values for each individual sample (five normal and
five cancer), expressed as % input.
Figure 5 Combined ChIP-MeDIP analysis at a single locus is
sufficient to demarcate normal cervical tissues from cervical
cancer. 5mC data for five normal and five cancer samples is
compared (Figure 4) to either 5mC/Pol II or 5mC/H3K27m3 ratio.
The red horizontal line demarcates the highest value for the normal
tissues.
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Page 11 of 15nephropathy [44,53]. The leptin deficient insulin resis-
tant C57BL/6J ob/ob mice are mildly hyperglycemic and
do not develop kidney lesions resembling human dia-
betes [59]. We used chromatin from the kidneys of
these strains and their respective controls in the com-
bined ChIP-MeDIP assay. Blood glucose levels in these
strains were as follows (in mg/dl): C57BL/6J 65 ± 4;
C57BL/6 ob/ob 112 ± 13; FVB 197 ± 15; and FVB
OVE26 649 ± 22.
Matrix ChIP-MeDIP analysis revealed lower 5mC
levels at the MCP-1 gene in the diabetic OVE26 mice
compared to the normal FVB controls (Figure 6A,r o w
1). The lower DNA methylation levels in the diabetic
mice were associated with higher levels of Pol II (row 2)
as well as higher levels of H3K9,14Ac (row 3). To quan-
titate the relationship between DNA methylation and
transcription we calculated the ratio of 5mC levels to
Pol II density in each one of the individual kidney sam-
ples. The average 5mC/Pol II ratio at the MCP-1 gene
in the OVE26 diabetic kidneys was less than 50% of that
calculated in the normal FVB kidney. This analysis sug-
gests that diabetes induces reciprocal changes in DNA
methylation and Pol II transcription at the renal MCP-1
gene. To our knowledge this is the first demonstration
that diabetic milieu alters DNA methylation at a specific
gene locus in the kidney, an effect that may be contri-
buting to increased transcription of the cognate gene. In
contrast to the MCP-1 gene, there were no differences
detected at the TGF-b1 locus. This suggests that early
diabetes-induced chromatin changes are gene selective.
Interestingly, we did not detect any differences between
the lean and obese C57BL/6J strains in the kidney at
either the MCP-1 or TGF-b1 gene (Figure 6B). Taken
together, these results show that the combined Matrix
ChIP-MeDIP platform can be applied to the analysis of
chromatin and transcription processes in chronic kidney
disease. Moreover, as in the case of cancer (Figure 5)
the ratio of 5mC/Pol II at a relevant gene(s) may serve
as a potential biomarker for kidney disease using either
renal biopsy specimens or the hundreds of renal cells
that are normally shed in urine every day [60].
Although compared to antibody-coated beads, the
microplate ChIP and MeDIP offers higher throughput
and better performance using 5mC (Figure 3B) and
other selected antibodies [47] there are potential limita-
tions that remain to be tested and solved. In the micro-
plate assay the detection at selected genomic sites is in
the range 0.5-50% of 100-200 ng input DNA/well
[33,36,47]. Thus, for most of the antibodies tested the
quantity of ChIP DNA output is in the range of few
nanograms or less, limiting the number of genomic sites
that can be probed by real-time PCR. In contrast to
antibody-coated wells, the volume of antibody-coated
beads in a single pull-down can be easily scaled up to
increase the DNA yield to the range of 500-1000 ng
needed in either microarrays or sequencing platforms
for genome-wide ChIP or M e D I Ps t u d i e s .T h u s ,f o r
most antibodies, including that to 5mC, the current
microplate format remains to be adapted for genome-
wide studies which may require the addition of whole
genome amplification [61].
The microwell platform can be used to probe a wide
range of genome-associated epitopes using either poly-
clonal or monoclonal antibodies [33,36,47,62]. Notably,
with some antibodies the microplate performs better
than the beads (Figure 3B and [47]). Given that there
could be cases when genome-associated epitopes are not
well detected by ChIP antibody-coated microplates,
when necessary, the beads assay ought to be considered
as an alternative for that specific epitope(s).
Conclusions
We have developed a microplate-based MeDIP method
that has several important advantages over beads assays.
i) It simplifies the entire procedure eliminating the need
for centrifugation or magnets and uses fewer buffers. ii)
It is more sensitive and has a lower level of non-specific
binding compared to beads. iii) The microplate ChIP
platform is sufficiently sensitive to probe genome-asso-
ciated enzymes such as kinases and phosphatases
[33,36]. Thus, the capabilityt os i m u l t a n e o u s l ya s s a y
DNA methylation, histone marks and signal transducers
on the same plate(s) should facilitate mapping genomic
pathways at selected genes. iv) The combined microplate
ChIP-MeDIP and real-time PCR assays allows one to
generate hundreds of ChIP-MeDIP records at a time to
profile complex genomic events at selected disease-
related gene loci. v) As the cost of genome-wide sequen-
cing continues to decrease and user-friendly software
tools becomes available, the Matrix ChIP-MeDIP output
of hundreds of DNA samples could be potentially
adapted to genome-wide studies and be generally afford-
able. Finally, the recent advances in DNA sequencing
are generating extraordinary volumes of genome-wide
chromatin data. Still, most of these studies have been
done in cell cultures and largely lack mechanistic and
functional information [63]. These valuable data
resources are freely available providing great opportu-
nities to integrate information across the different cell
types and species allowing one to formulate mechanistic
and functional hypothesis. The capability of Matrix
ChIP-MeDIP to simultaneously study Pol II, histones,
gene-associated transducers/enzymes and DNA methyla-
tion provides an unprecedented opportunity to better
define the dynamic chromatin and transcription at spe-
cific gene loci.
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